Table 5.

Late TRAEs (with frequency ≥ 1% for Grade 1 + 2 toxicity).

Late TRAE (N = 157)	Grade 1 and 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
Dysphagia	4 (2.6)	3 (1.9)	0
Thirst *1	4 (2.6)	0	0
Skin disorder *2	1 (0.6)	2 (1.3)	0
Soft tissue infection	0	2 (1.3)	0
Hyperamylasemia	0	2 (1.3)	0
Papilloedema	0	2 (1.3)	0
Visual acuity reduced	2 (1.3)	0	0
Radiation necrosis (site unknown)	2 (1.3)	0	0
Decreased appetite *3	2 (1.3)	0	0
Pneumonia aspiration	0	0	1 (0.6)
Abscess bacterial (site unknown)	0	1 (0.6)	0
Brain abscess	0	1 (0.6)	0
Infected neoplasm	0	1 (0.6)	0
Cranial nerve paralysis	0	1 (0.6)	0
Cataract	0	1 (0.6)	0
Pneumonitis	0	1 (0.6)	0
Oroantral fistula	0	1 (0.6)	0
Ulcer haemorrhage	0	1 (0.6)	0
Radiation retinopathy	0	1 (0.6)	0
Osteoradionecrosis	0	1 (0.6)	0

*¹ Including the description “dry mouth”. *² Including the descriptions “skin exfoliation” and “skin ulcer”. *³ Including the description “hypophagia”. All notations conform to MedDRA/J version 25.1. Abbreviations: TRAEs, treatment-related adverse events; MedDRA, Medical Dictionary for Regulatory Activities.